News about "semaglutide "

US FDA Proposes Excluding Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List

The US Food and Drug Administration (FDA) proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need for compounding these GLP-1 drugs by outsourcing facilities.

Semaglutide | 04/05/2026 | By News Bureau

OneSource and Orbicular Receive US FDA Tentative Approval for Generic Semaglutide

OneSource and Orbicular secure US FDA tentative approval for generic semaglutide injection, advancing ANDA filing for Ozempic with manufacturing support from OneSource.

Semaglutide | 22/04/2026 | By News Bureau |  165

PrecisionLife and Ovation Partner to Launch GLP-1 stratification LDT and GLP-1 DNA Test in H2 2026

PrecisionLife and Ovation partner to launch GLP-1 stratification LDT and consumer DNA test in 2026, with early data showing distinct genetic markers for weight loss and glycemic control.

Semaglutide | 16/04/2026 | By News Bureau

UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment

The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.

Semaglutide | 15/04/2026 | By News Bureau |  130

Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting

Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.

Semaglutide | 09/04/2026 | By News Bureau |  170

NICE Recommends Weekly Semaglutide Injection to Prevent Heart Attacks and Strokes

NICE advises use of semaglutide injections for patients with prior cardiovascular conditions and excess weight to lower risk of future serious events.

Semaglutide | 04/04/2026 | By News Bureau

From Generics to Biologics: Semaglutide Reshapes Pharma Manufacturing in India

The recent developments around semaglutide in India—triggered by patent expiry and rapid domestic entry—are poised to significantly reshape the country’s pharmaceutical manufacturing landscape.

Semaglutide | 23/03/2026 | By Darshana |  173

Zydus and Torrent Pharma Sign Licensing Deal to Co-Market Semaglutide in India

Zydus Lifesciences and Torrent Pharmaceuticals have entered a licensing agreement to co-market Semaglutide injection in India, aiming to improve access for patients with poorly controlled Type 2 Diabetes Mellitus and support chronic weight management through advanced, innovative therapy.

Semaglutide | 19/03/2026 | By News Bureau |  173

Samsung Bioepis and Epis NexLab Partner G2GBIO to Develop Long-Acting Semaglutide

Samsung Bioepis and Epis NexLab have signed a research collaboration and licensing agreement with G2GBIO to develop novel assets, including long-acting semaglutide, using G2GBIO’s proprietary microsphere drug delivery technology.

Semaglutide | 16/03/2026 | By News Bureau |  109

UK MHRA Updates Safety Information on Semaglutide Over Rare NAION Vision Risk

UK MHRA flags a very rare risk of NAION linked to semaglutide, urging patients to seek immediate medical attention for sudden changes in vision.

Semaglutide | 07/02/2026 | By News Bureau |  568